Skip to content

MABVAX THERAPEUTICS HOLDINGS, INC.: 10-Q filed 2017-11-07

What MABVAX THERAPEUTICS HOLDINGS, INC. reported in its quarterly report filed 2017-11-07 (fiscal Q3 2017): 29 published measures, 77 facts as tagged in accession 0001654954-17-010141.

This filing

Form
10-Q (quarterly report)
Filed
2017-11-07
Fiscal period
fiscal Q3 2017
Accession
0001654954-17-010141 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MABVAX THERAPEUTICS HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-09-3011,098,583USD
At 2016-12-3112,020,290USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-09-308,578,167USD
At 2016-12-318,677,768USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-09-302,520,416USD
At 2016-12-313,342,522USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-09-303,052,778USD
At 2016-12-313,979,290USD
At 2016-09-306,941,213USD
At 2015-12-314,084,085USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-3,080,161USD92
2017-01-01 to 2017-09-30-14,424,883USD273
2016-07-01 to 2016-09-30-4,357,748USD92
2016-01-01 to 2016-09-30-12,550,493USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-01-01 to 2017-09-3021,072USD273
2016-01-01 to 2016-09-30412,498USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2017-07-01 to 2017-09-300USD92
2017-01-01 to 2017-09-300USD273
2016-07-01 to 2016-09-300USD92
2016-01-01 to 2016-09-30148,054USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-09-30-101,046,557USD
At 2016-12-31-78,262,261USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-09-30619,208USD
At 2016-12-31731,712USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-09-304,516,371USD273
2016-01-01 to 2016-09-303,459,992USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-2,848,690USD92
2017-01-01 to 2017-09-30-13,681,746USD273
2016-07-01 to 2016-09-30-4,091,697USD92
2016-01-01 to 2016-09-30-11,821,162USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-09-303,474,775USD
At 2016-12-314,293,978USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-07-01 to 2017-09-30138,642USD92
2017-01-01 to 2017-09-30445,934USD273
2016-07-01 to 2016-09-30266,057USD92
2016-01-01 to 2016-09-30729,350USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-09-306,393,046USD
At 2016-12-315,690,634USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-09-301,550,113USD
At 2016-12-311,137,903USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2017-09-306,826,003USD
At 2016-12-316,826,003USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-07-01 to 2017-09-302,848,690USD92
2017-01-01 to 2017-09-3013,681,746USD273
2016-07-01 to 2016-09-304,091,697USD92
2016-01-01 to 2016-09-3011,969,216USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-07-01 to 2017-09-301,017,061USD92
2017-01-01 to 2017-09-306,168,125USD273
2016-07-01 to 2016-09-301,671,181USD92
2016-01-01 to 2016-09-304,967,695USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-09-3018,924,085shares
At 2016-12-316,296,110shares

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2017-09-304,054,175USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-09-30178,597USD
At 2016-12-31168,597USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-09-30177,016USD
At 2016-12-31144,394USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2017-09-301,502,505USD
At 2016-12-311,218,641USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-6,200,161USD92
2017-01-01 to 2017-09-30-22,784,296USD273
2016-07-01 to 2016-09-30-4,357,748USD92
2016-01-01 to 2016-09-30-12,550,493USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-301,831,629USD92
2017-01-01 to 2017-09-307,513,621USD273
2016-07-01 to 2016-09-302,420,516USD92
2016-01-01 to 2016-09-307,001,521USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-01-01 to 2017-09-30122,315USD273
2016-01-01 to 2016-09-3060,058USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-231,471USD92
2017-01-01 to 2017-09-30-743,137USD273
2016-07-01 to 2016-09-30-266,051USD92
2016-01-01 to 2016-09-30-729,331USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2017-01-01 to 2017-09-30443,495USD273
2016-01-01 to 2016-09-30379,560USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-09-30403,210USD273
2016-01-01 to 2016-09-30-2,476,130USD274

Inspect the source

Entity
MABVAX THERAPEUTICS HOLDINGS, INC. / CIK 0001109196
Captured
SEC response SHA-256
2dc5df2a7df3f38f707cc55c9468803a1fe6d3f0a8c8a7e3bdc387c99f005336

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001109196.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))